Frontage Laboratories | 01-Dec-2019
| Technical / White Paper
Biologics are complex large molecules derived from living organisms or manufactured from cells, and they have inherent structural heterogeneity. Indeed,...
Frontage Laboratories | 01-Oct-2019
| Technical / White Paper
Over the years, the pharmaceutical industry has made steady progress in improving the safety of drugs in development. Consequently, in 2015, only 14 percent...
Frontage Laboratories | 01-Oct-2019
| Technical / White Paper
Frontage is the first and only laboratory to validate Quanterix’ Simoa HD1 Analyzer for performing immunoassays. Most of the advanced instruments used...
Frontage Laboratories | 21-Aug-2019
| Technical / White Paper
Immunogenicity is the leading reason that biologics fail in clinical trials, and thus it has become imperative for drug development programs to include...
BBK Worldwide | 24-Jul-2019
| Technical / White Paper
Despite growing evidence, the myth that physicians won’t refer patients to clinical trials persists, perpetuated by the belief that they fear losing their...
In May 2018 Outsourcing-Pharma.com, in association with InnovoCommerce, conducted its second annual ‘state of the industry’ survey on its user base of...
Catalent Pharma Solutions | 05-Mar-2018
| Technical / White Paper
When planning a clinical trial, overlooking the importance of primary packaging can be a mistake. From stability concerns to labeling to patient compliance...
Vetter Pharma International GmbH | 07-Nov-2017
| Technical / White Paper
In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...
